Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for Chronic Lymphocytic Leukemia (CLL), a type of cancer that affects the blood and bone marrow. The study involves three different treatment approaches. The first approach combines Obinutuzumab, a medication given through an infusion into the vein, with Chlorambucil, a chemotherapy drug taken as a tablet. The second approach combines Obinutuzumab with Acalabrutinib (also known as ACP-196), a medication taken orally as a tablet or capsule. The third approach uses Acalabrutinib alone as a monotherapy.

The purpose of the study is to evaluate the effectiveness of these treatments in people who have not received prior treatment for their CLL. Participants will be randomly assigned to one of the three treatment groups. The study will monitor the progress of the disease and the response to the treatment over a period of time. Participants will receive regular check-ups and assessments to track their health and any changes in their condition.

The study aims to provide valuable information on how well these treatments work in managing CLL and to compare their effectiveness. Participants will be closely monitored for any side effects or adverse reactions to the treatments. The study will help in understanding which treatment option might be the most beneficial for patients with CLL.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are assigned to one of three groups, known as arms. Each arm involves a different treatment plan for chronic lymphocytic leukemia.

  2. Step 2

    Treatment arm A

    Participants in Arm A receive a combination of obinutuzumab and chlorambucil. Obinutuzumab is administered as an intravenous infusion, while chlorambucil is taken orally as a tablet.

  3. Step 3

    Treatment arm B

    Participants in Arm B receive a combination of acalabrutinib and obinutuzumab. Acalabrutinib is taken orally in the form of a capsule, and obinutuzumab is given as an intravenous infusion.

  4. Step 4

    Treatment arm C

    Participants in Arm C receive acalabrutinib alone. This medication is taken orally in the form of a capsule.

  5. Step 5

    Medication dosage and frequency

    The specific dosage and frequency of each medication are determined by the study protocol and are based on the participant's health status and response to treatment.

  6. Step 6

    Monitoring and assessments

    Throughout the study, participants undergo regular monitoring and assessments to evaluate the effectiveness of the treatment and to check for any side effects. This includes laboratory tests and possibly imaging studies.

  7. Step 7

    Study duration

    The study is expected to continue until September 2025. Participants will be involved in the study for the duration specified in their treatment plan, which may vary depending on their response to the treatment.

Who can join the trial?

18 criteria

  • Men and women who are 65 years or older, or between 18 and 64 years old if they meet certain health criteria.
  • Have a specific level of kidney function, measured by a test called the Cockcroft-Gault equation.
  • Have a score higher than 6 on a health assessment called the Cumulative Illness Rating Scale-Geriatric (CIRS-G).
  • Have an ECOG performance status of 0, 1, or 2, which is a scale that measures how well a person can perform daily activities.
  • Have a diagnosis of **CD20+ Chronic Lymphocytic Leukemia (CLL)**, which is a type of blood cancer.
  • Have active disease that meets at least one of the following criteria for needing treatment:
    • Worsening anemia (low red blood cells) or thrombocytopenia (low platelets).
    • Enlarged spleen or lymph nodes that are getting bigger or causing symptoms.
    • Increasing number of white blood cells over a short period.
    • Autoimmune anemia or thrombocytopenia not responding well to standard treatment.
    • Symptoms like significant weight loss, fatigue, fever, or night sweats without infection.
    • Meet certain blood test requirements, such as having enough neutrophils (a type of white blood cell) and platelets.
    • Have liver function tests within a certain range.
    • Have kidney function that is at least a certain level.
    • Be able to attend all outpatient treatments, lab tests, and scans.
    • Women who can have children must use effective birth control during the study and for a specified time after the last dose of medication.
    • Men who can father children must use effective birth control during the study and for a specified time after the last dose of medication.
    • Men must not donate sperm during the study and for a specified time after the last dose of medication.
    • Be willing and able to follow the study schedule and requirements, and provide written consent to participate.

Who cannot join the trial?

6 criteria

  • Patients who have received treatment for Chronic Lymphocytic Leukemia before cannot participate. This means if you have already been treated for this type of leukemia, you are not eligible.
  • Patients with other serious health conditions that might interfere with the study are not eligible. This means if you have another major illness, you might not be able to join.
  • Patients who are pregnant or breastfeeding cannot participate. This is to ensure the safety of both the mother and the baby.
  • Patients who are unable to follow the study procedures or attend the required visits are not eligible. This means if you cannot commit to the study schedule, you cannot join.
  • Patients with a history of severe allergic reactions to the study medications cannot participate. This is to prevent any serious health risks.
  • Patients who are currently participating in another clinical trial are not eligible. This is to avoid any interference with the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Obinutuzumab

    is a medication used in this trial to treat chronic lymphocytic leukemia (CLL). It is a type of antibody therapy that helps the immune system target and destroy cancer cells. In this study, it is used in combination with other treatments to evaluate its effectiveness.

  • Chlorambucil

    is a chemotherapy drug that is used to treat CLL. It works by slowing or stopping the growth of cancer cells. In this trial, chlorambucil is combined with obinutuzumab to assess their combined effect on the disease.

  • ACP-196

    , also known as acalabrutinib, is a medication used in this study to treat CLL. It is a type of targeted therapy that blocks certain proteins needed by cancer cells to grow. In the trial, acalabrutinib is tested both in combination with obinutuzumab and as a standalone treatment to determine its effectiveness in managing the disease.

What is already known about the treatment

  • Obinutuzumab

    This medication is administered intravenously and is used in the treatment of Chronic Lymphocytic Leukemia (CLL). It is currently being studied in clinical trials to assess its effectiveness, particularly in combination with other drugs. Obinutuzumab works by targeting a specific protein on the surface of certain white blood cells, leading to their destruction. It is classified as a monoclonal antibody, which is a type of targeted cancer therapy.

  • Chlorambucil

    This medication is taken orally and is used to treat Chronic Lymphocytic Leukemia (CLL). It is well-established in medical literature as a chemotherapy agent. Chlorambucil works by interfering with the DNA replication process in cancer cells, preventing their growth and division. It is classified as an alkylating agent, which is a type of chemotherapy drug.

  • Acalabrutinib

    This medication is administered orally and is used in the treatment of Chronic Lymphocytic Leukemia (CLL). It is currently being evaluated in clinical trials for its effectiveness, especially in combination with other treatments. Acalabrutinib works by inhibiting a specific enzyme involved in the growth and survival of cancer cells. It is classified as a Bruton’s tyrosine kinase (BTK) inhibitor, which is a type of targeted therapy.

Investigated diseases

Chronic Lymphocytic Leukemia – Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It is characterized by the production of an excessive number of abnormal lymphocytes, a type of white blood cell. These abnormal cells accumulate over time, crowding out healthy blood cells and impairing the immune system. CLL typically progresses slowly, and many individuals may not experience symptoms for years. As the disease advances, it can lead to symptoms such as fatigue, swollen lymph nodes, and an increased risk of infections. The progression of CLL varies among individuals, with some experiencing a more aggressive form of the disease.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-509348-84-00Protocol codeACE-CL-007Estimated enrolment535 patientsSponsorAcerta Pharma B.V.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.